Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remdesivir in Mild and Moderate COVID-19
NCT04252664Phase 3Suspended
- Sponsor
- Capital Medical University
- Start
- Feb 2020
- Primary completion
- Apr 2020
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of remdesivir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Capital Medical University. Primary endpoint: Time to Clinical Recovery at 28 days. Started Feb 2020; status: suspended.
02
Drugs
remdesivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04252664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04252664.